·临床论著：1594摘要目的：研究巴曲酶辅助治疗重度突发性耳聋（Suddendeafness，SD）患者的临床疗效。方法：收集我院2018年1月至2022年1月收治的92例重度SD患者，按治疗方案不同，分成基本治疗组（n=46）和巴曲酶辅助治疗组（n=46)。两组均给予高压氧、溶栓、抗凝、扩张血管等对症治疗，基本治疗组在常规对症治疗的基础上，在鼓室、耳后骨膜下局部注射琥珀酸钠甲泼尼龙（Methylprednisolonesodiumsuccinate，MPSS）治疗。巴曲酶辅助治疗组在治疗组的治疗基础上给予巴曲酶辅助治疗。治疗1个疗程后，对比两组总有效率、治疗前后听力水平、耳鸣残疾量表（Tinnitushandicapinventory，THI）评分、炎性因子[超敏C反应蛋白（HighsensitivityC-reactiveprotein，hs-CRP）、白细胞介素-6（Interleukin-6，IL-6）、肿瘤坏死因子-α（Tumornecrosisfactor-α，TNF-α）l、不良反应发生率。结果：治疗1疗程后，巴曲酶辅助治疗组总有效率高于基本治疗组（P<0.05)；听力水平、THI评分高于基本治疗组（P<0.05)；血清hs-CRP、TNF-α、IL-6水平低于基本治疗组（P<0.05)；两组不良反应总发生率对比，无显著差异（P>0.05）。结论：巴曲酶辅助治疗重度SD效果显著，可有效缓解耳鸣，改善听力，调节血管活性因子水平，减轻机体炎性反应，促进病情恢复，且安全性高。关键词：甲泼尼龙琥珀酸钠；巴曲酶；重度突发性耳聋；听力水平Clinicalefficacyofbatroxobininadjuvanttreatmentofseveresuddendeafness(1.DepartmentofOtolaryngology,TaikangPeople'sHospital,Zhoukou461400,Henan,China;2.DepartmentofOtolaryngology,TheFirstAffiliatedHospitalofZhengzhouUniversity,Zhengzhou450000,China;3.DepartmentofAbstractObjective:Tostudytheclinicalefficacyofbatroxobinintheadjuvanttreatmentofseveresuddendeafness(SD).Methods:Ninety-twopatientswithsevereSDadmittedtoourhospitalfromJanuary2018toJanuary2022werecollectedanddividedintobasictreatmentgroup(n=46)andbatroxobinadjuvanttreatmentgroup(n=46)accordingtodifferenttreatmentplans.Bothgroupsweregivensymptomatictreatmentsuchashyperbaricoxygen,thrombolysis,anticoagulation,anddilationofbloodvessel.Basedonconventionalsymptomatictreatment,basictreatmentgroupwastreatedwithmethylprednisolonesodiumsuccinate(MPSS)inthetympaniccavityandundertheearperiosteum.Batroxobinadjuvanttrea...
